News

Sundyota ties up with Italian firm to launch probiotic products in India

Our Bureau Ahmedabad | Updated on April 11, 2018 Published on April 11, 2018

Plans to set up formulations facility near Ahmedabad; in marketing tie-up with Cipla

As a non-medicinal answer to the gastrointestinal problems such as diarrhoea, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD), the Ahmedabad-based Sundyota Numandis has tied up with Italian Probiotical to offer world’s most researched probiotic product, Lactobacillus rhamnosus GG, in Indian market.

As per the pact, Sundyota Numandis procures coated oro-soluble L rhamnosus GG from Probiotical, Italy and manufacture it for the Indian market. Sundyota Numandis markets the product under the brand name of SuperFlora GG. The company has also inked a strategic agreement with pharma major Cipla to market in tandem the same probiotic product. Cipla’s product is named ‘Unobiotics’ and is available as a 1 gram sachet priced at ₹45.

New facility

“Currently, we are getting our product manufactured at Una in Himachal Pradesh through a third party. But we plan to set up our own new formulations facility at Changodar near Ahmedabad, with an investment of about ₹80 crore. The plant will be ready by November-December. We will supply the product to Cipla and they will market it under their brand,” said Dinesh Arora, managing director and CEO, Sundyota Numandis. The proposed manufacturing facility will have capacity to make 51 crore sachets per annum, with additional capacity to make capsules, liquids and tablets.

Lactobacillus rhamnosus GG is meant to support gastro-intestinal health and general well-being in children as well as adults with no adverse effects.

After extensive scientific studies on probiotic, Sundyota Numandis introduced the probiotic in a technologically superior and consumer compliant oro-dispersible powder form which is stable in Indian climate and called as Microbac GG. The sensitivity of L rhamnosus GG does not allow it to survive in climatic conditions of high temperature and humidity , it necessitates a technological advancement to increase its viability and stability.

“Lactobacillus rhamnosus GG is globally the number one choice amongst probiotics. The Indian probiotic market is valued at approximately ₹1000 crore and is growing at a rate of 15 per cent. We will be manufacturing 1 million sachets of Microbac GG every month. In future, we will also introduce L rhamnosus GG in various formulations like drops and capsules,” Arora said.

Published on April 11, 2018
This article is closed for comments.
Please Email the Editor